ArticleHealth and quality of life outcomes2019
Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.
Article in Health and quality of life outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06030245 (Clostridioides Difficile Infection), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clostridioides Difficile Infection: Prospective Cohort Analyzing CLInic Evolution and Bacterial Clearance
Who cites it
22 citing papers in PubMed.
- Cost-Effectiveness of Hospital-at-Home and Fecal Microbiota Transplantation in Treating Older Patients With Clostridioides difficile.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Malaysia: Epidemiological Data Update.Pulmonary therapy · 2026Article
- Article
- Patient Satisfaction Scale Following a Laxative for Antibiotic Washout Prior to Oral Microbiome Therapy.Advances in therapy · 2025Article
- Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.BMC infectious diseases · 2024Observational
- Cost-Effectiveness of Universal Asymptomatic Preoperative SARS-CoV-2 Polymerase Chain Reaction Screening: A Cost-Utility Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis.PloS one · 2024Article
- Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.Infectious diseases and therapy · 2024Article
- Interaction of Clostridioides difficile infection with frailty and cognition in the elderly: a narrative review.European journal of medical research · 2023Review
- Assessment of retrospective collection of EQ-5D-5L in a US COVID-19 population.Health and quality of life outcomes · 2023Article
- Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With RecurrentOpen forum infectious diseases · 2023Article
- Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review.Infectious diseases and therapy · 2023Review
- The burden of CDI in the United States: a multifactorial challenge.BMC infectious diseases · 2023Review
- Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.Journal of managed care & specialty pharmacy · 2022Article
- Health-related quality of life in patients with recurrentTherapeutic advances in gastroenterology · 2022Article
- Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.Clinical therapeutics · 2021Article
- A prospective, observational study of fidaxomicin use forThe Journal of international medical research · 2021Observational
- Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Article
- Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review.Health economics review · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClostridium difficile infection (CDI) is associated with a substantial Quality of life impact on patients that has not been so far measured with a generic validated instrument.
methodsA prospective study was performed in 7 French acute-care settings in patients presenting with a bacteriologically-confirmed CDI. The EQ-5D-3 L was filled in by patients at 7 ± 2 days after CDI diagnosis to describe their state of health at that date as well as their state of health immediately before the CDI episode (baseline). Individual utility decrement was obtained by subtracting the corresponding utilities. The Quality Adjusted Life Year (QALY) loss was calculated by multiplying the days spent from baseline to the date of the interview, by the decrement of utility. A multivariate analysis of variance of the utility decrement according to CDI and patients characteristics was performed.
resultsEighty patients were enrolled (mean age: 69.4 years, 55% females). The utility scores dropped from a mean 0.542 (SD: 0.391) at baseline to 0.050 (SD: 0.404) during the CDI episode with a mean adjusted utility decrement of 0.492 (SD: 0.398) point. This decrement increased significantly with CDI severity (Zar score ≥ 3) (p = 0.001), in patients with a positive baseline utility (p = 0.032), in women as compared to men (p = 0.041) and in patients aged more than 65 years (p = 0.041). No association with the Charlson index was found. The associated QALY loss not integrating the excess mortality was 0.028 (SD: 0.053).
conclusionsThe impact on quality of life of CDI episodes is major and translates in a substantial QALY loss despite their short duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.